Market Place
Sourcing Support
Annovis Bio Gets US Patent For TBI Treatment With Buntanetap
24 Jul 2024 //
GLOBENEWSWIRE
Annovis Bio FDA-Approved To Use New Buntanetap Crystal Form
16 Jul 2024 //
GLOBENEWSWIRE
Annovis Bio Announces New Data From Phase III Parkinson`s Study
02 Jul 2024 //
GLOBENEWSWIRE
Annovis Bio Files Patent for New Composition of Matter for Buntanetap
26 Jun 2024 //
GLOBENEWSWIRE
Annovis Bio’s Buntanetap Found Safe &Effective in High-Risk Alzheimer`s Patients
11 Jun 2024 //
GLOBENEWSWIRE
Annovis Unblinded Buntanetap Phase 3 Parkinson`s Data
09 May 2024 //
GLOBENEWSWIRE
Annovis Announces Publication That Supports Buntanetap`s MOA in Humans
01 Apr 2024 //
GLOBENEWSWIRE
Annovis Bio Provides Data update for the Ph II/III Study of Buntanetap in AD`s
20 Mar 2024 //
GLOBENEWSWIRE
Annovis Bio Announces Last Patient Last Visit in the Phase II/III of Buntanetap
14 Feb 2024 //
GLOBENEWSWIRE
Annovis Announces Last Patient Last Visit in the Phase III Study of Buntanetap
05 Dec 2023 //
GLOBENEWSWIRE
Annovis Bio Receives Recommendation to Continue Phase 2/3 Trial of Buntanetap
30 Oct 2023 //
BUSINESSWIRE
Annovis Bio Receives Excellent Safety Rating and Positive Recommendation
20 Jun 2023 //
BUSINESSWIRE
Annovis Bio Announces Issuance of U.S. Patent Covering Buntanetap
27 Apr 2023 //
GLOBENEWSWIRE
Annovis Announces Approval for European Union Trial Sites for PIII of Buntanetap
08 Feb 2023 //
PR NEWSWIRE
Annovis Announces Patient Enrollment Update For Phase 3 Of Buntanetap
25 Jan 2023 //
PR NEWSWIRE
Annovis Announces FDA Authorization to Proceed with Ph 2/3 Trial for Buntanetap
06 Oct 2022 //
PRNEWSWIRE
Annovis Bio Announces Positive FDA Notice For Buntanetap PIII Trial In PD
07 Jul 2022 //
PRNEWSWIRE
Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Actio
07 Sep 2021 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.